Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Statin intolerant and statin tolerant~* Fasting LDL-C between 130 mg/dL and 220 mg/dL~* Fasting triglyceride less than or equal to 400 mg/dL~* Body mass index (BMI) between 18 and 45 kg/m2~Key Exclusion Criteria:~* History or current clinically significant cardiovascular disease~* History or current type 1 diabetes or uncontrolled type 2 diabetes~* Use of metformin or thiazolidinediones (TZD) within 3 months of screening~* History of joint symptoms difficult to differentiate from myalgia~* Uncontrolled hypothyroidism~* Liver disease or dysfunction~* Renal dysfunction or nephritic syndrome~* Gastrointestinal (GI) conditions or prior GI procedures~* HIV or AIDS~* History or malignancy~* History or drug or alcohol abuse within last 2 years~* Use of experimental or investigational drugs within 30 days of screening~* Use of ETC-1002 in a previous clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 120 mg/day (Type: EXPERIMENTAL): Orally, once daily in morning as capsules
- ETC-1002 180 mg/day (Type: EXPERIMENTAL): Orally, once daily in morning as capsules
- ezetimibe 10mg/day (Type: ACTIVE_COMPARATOR): Orally, once daily in morning as capsules
- ETC-1002 120 mg/day + ezetimibe 10mg/day (Type: EXPERIMENTAL): Orally, once daily in morning
- ETC-1002 180 mg/day + ezetimibe 10mg/day (Type: EXPERIMENTAL): Orally, once daily in morning

Based on this trial design, predict the completion outcome and termination type (if applicable).